RCT | Rivaroxaban shows promise compared to Enoxaparin in the acute phase of an acute coronary syndrome

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial – JAMA Network Open

Invited Commentary: Rivaroxaban for Patients With Acute Coronary Syndromes—Where Do We Stand? – JAMA Network Open

Commentary on Twitter

The H-REPLACE RCT: short-term rivaroxaban (5mg 2x/day) was noninferior to enoxaparin in safety + efficacy during 6-month follow-up among patients with acute coronary syndrome who missed the primary reperfusion window and before selective revascularization. https://t.co/TIHOwGSWjJ

— JAMA Network Open (@JAMANetworkOpen) February 10, 2023